NARA Discovery
Article Details
← Back to Search Results
Journal Article

Estrogenic in vitro evaluation of zearalenone and its phase I and II metabolites in combination with soy isoflavones

Dino Grgic; Andrea Betschler; Rebeka Früholz; Barbara Novak; Elisabeth Varga; Doris Marko
Archives of Toxicology · Vol. 96, Issue 12 · pp. 3385-3402 · 2022

Abstract

Humans and animals are exposed to multiple substances in their food and feed that might have a negative health impact. Among these substances, the Fusarium mycoestrogen zearalenone (ZEN) and its metabolites α-zearalenol (α-ZEL) and α-zearalanol (α-ZAL) are known to possess endocrine disruptive properties. In a mixed diet or especially animal feed, these potential contaminants might be ingested together with naturally occurring phytoestrogens such as soy isoflavones. So far, risk assessment of potential endocrine disruptors is usually based on adverse effects of single compounds whereas studies investigating combinatorial effects are scarce. In the present study, we investigated the estrogenic potential of mycoestrogens and the isoflavones genistein (GEN), daidzein (DAI) and glycitein (GLY) as well as equol (EQ), the gut microbial metabolite of DAI, in vitro alone or in combination, using the alkaline phosphatase (ALP) assay in Ishikawa cells. In the case of mycoestrogens, the tested concentration range included 0.001 to 10 nM with multiplication steps of 10 in between, while for the isoflavones 1000 times higher concentrations were investigated. For the individual substances the following order of estrogenicity was obtained: α-ZEL > α-ZAL > ZEN > GEN > EQ > DAI > GLY. Most combinations of isoflavones with mycoestrogens enhanced the estrogenic response in the investigated concentrations. Especially lower concentrations of ZEN, α-ZEL and α-ZAL (0.001—0.01 nM) in combination with low concentrations of GEN, DAI and EQ (0.001—0.1 µM) strongly increased the estrogenic response compared to the single substances.

Bibliographic Information

JournalArchives of Toxicology
PublisherSpringer
Publication Date2022-12-01
Publication Year2022
Volume96
Issue12
Pages3385-3402
Document TypeJournal Article
Print ISSN0340-5761
eISSN1432-0738
DOI10.1007/s00204-022-03358-3

Access Information

NARA Access Coverage1930-01-01~Current
Journal Homepagehttps://www.springer.com/journal/204
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.